MGMT and central nervous system cancer: A variety of methods and platforms have been developed to detect MGMT promoter methylation in gliomas, including methylation-specific PCR (MSP), quantitative methylation-specific PCR (qMSP), multiplex ligation-dependent probe amplification (MLPA), pyrosequencing (PSQ), methylation-sensitive high-resolution melting (MS-HRM), Next Generation Sequencing (NGS) and immunohistochemistry (IHC) [25].